表紙
市場調査レポート

低血糖症 : パイプライン分析

Hypoglycemia - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229785
出版日 ページ情報 英文 77 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.06円で換算しております。
Back to Top
低血糖症 : パイプライン分析 Hypoglycemia - Pipeline Review, H2 2016
出版日: 2016年07月20日 ページ情報: 英文 77 Pages
概要

低血糖症は、血液中のグルコース(ブドウ糖)水準が低下したときに発生します。グルコースは人体のエネルギー源として重要です。低血糖症は突然に発症しますが、少量の血糖値の高い血液を消費することで容易・迅速に制御できます。低血糖の症状としては、空腹感や震え、神経質、冷や汗、めまい/朦朧状態、眠気、混乱、睡眠障害、不安感、脱力感などが挙げられます。睡眠中の低血糖の兆候としては、奇声や悪夢、発汗でパジャマやシーツが湿気ていること、起床時に疲れや苛立ちや困惑を感じていることなどがあります。更に、各種の血糖症治療薬の副作用としても現れます。低血糖症はまた、食事が不規則で量も少なかったり、身体活動が増加したり、アルコール飲料を摂取していたりするといった理由で、インスリン生産量を増加させるための注射や錠剤を利用している人々にも生じます。

当レポートでは、世界各国での低血糖症治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果をお届けします。

イントロダクション

  • 分析範囲

低血糖症の概要

治療薬の開発

  • 低血糖症向けパイプライン製品:概要
  • 低血糖症向けパイプライン製品:比較分析

各企業で開発中の低血糖症治療薬

大学/研究機関で研究中の低血糖症治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

低血糖症治療薬:開発中の製品の一覧(企業別)

低血糖症治療薬:研究中の製品の一覧(大学/研究機関別)

低血糖症治療薬の開発に従事している企業

  • Biodel Inc.
  • Eli Lilly and Company
  • Heptares Therapeutics Limited
  • Novartis AG
  • SkyePharma Plc
  • USV Limited
  • XERIS Pharmaceuticals, Inc.
  • XOMA Corporation
  • Zealand Pharma A/S

低血糖症:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別
  • 薬効分類別

薬剤のプロファイル

  • 低血糖症向け生物製剤
  • glucagon
  • pasireotide
  • GLP-1 受容体拮抗薬
  • terbutaline sulphate
  • XOMA-358
  • ZP-4207

低血糖症治療薬:最新の薬剤プロファイル

低血糖症治療薬:開発が休止状態の製品

低血糖症治療薬:開発が中止された製品

低血糖症関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8287IDB

Summary

Global Markets Direct's, 'Hypoglycemia - Pipeline Review, H2 2016', provides an overview of the Hypoglycemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hypoglycemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hypoglycemia
  • The report reviews pipeline therapeutics for Hypoglycemia by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hypoglycemia therapeutics and enlists all their major and minor projects
  • The report assesses Hypoglycemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hypoglycemia

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hypoglycemia
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hypoglycemia pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hypoglycemia Overview
  • Therapeutics Development
    • Pipeline Products for Hypoglycemia - Overview
  • Hypoglycemia - Therapeutics under Development by Companies
  • Hypoglycemia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Hypoglycemia - Products under Development by Companies
  • Hypoglycemia - Companies Involved in Therapeutics Development
    • Biodel Inc.
    • Eiger BioPharmaceuticals, Inc.
    • Eli Lilly and Company
    • Heptares Therapeutics Limited
    • Novartis AG
    • Sanofi
    • SkyePharma Plc
    • Therakind Limited
    • USV Limited
    • XERIS Pharmaceuticals, Inc.
    • XOMA Corporation
    • Zealand Pharma A/S
    • Zosano Pharma Corporation
  • Hypoglycemia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • Drug for Hypoglycemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • exendin-(9-39) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glucagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3143753 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3185643 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-900018 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pasireotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide for Hypoglycemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-438544 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • terbutaline sulphate MR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • XOMA-358 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZP-4207 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Hypoglycemia - Dormant Projects
  • Hypoglycemia - Discontinued Products
  • Hypoglycemia - Product Development Milestones
    • Featured News & Press Releases
      • Jun 13, 2016: Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia
      • May 10, 2016: Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery
      • Apr 27, 2016: XOMA Initiates XOMA 358 Proof-of-Concept Study in Patients with Hypoglycemia Post Gastric Bypass Surgery
      • Apr 04, 2016: XOMA Presented First Data from Novel Antibody Fragment to Address Severe Acute Hypoglycemia at the ENDO Meeting
      • Feb 04, 2016: Zealand initiates dosing of patients in Phase 2 with its stable glucagon analogue, ZP4207, for hypoglycemia in diabetes
      • Oct 26, 2015: XOMA Initiates Proof-of-Concept Study for XOMA 358 in Patients with Congenital Hyperinsulinism
      • Oct 13, 2015: Zosano Pharma Announces Positive Phase 2 Results for Its ZP-Glucagon Patch Program for Treatment of Severe Hypoglycemia
      • Sep 09, 2015: Results from a multiple-dose Phase Ib trial support the potential of Zealand's stable glucagon analogue, ZP4207, for the correction of mild to moderate hypoglycemia
      • Jun 26, 2015: Phase I trial results for Zealand's glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy
      • Jun 23, 2015: Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia
      • May 20, 2015: Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207
      • Mar 16, 2015: Biodel's Glucagon Formulation for Use in a Proprietary Auto-Reconstitution Device for the Treatment of Severe Hypoglycemia Meets Primary Efficacy Endpoint in Phase 1 Clinical Trial
      • Mar 07, 2015: XOMA Presents Positive Phase 1 XOMA 358 Data at the ENDO Meeting
      • Mar 05, 2015: XOMA Will Present XOMA 358 Phase 1 Data at ENDO 2015
      • Dec 04, 2014: Biodel Initiates Clinical Proof of Concept Study in Glucagon Emergency Management Program
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hypoglycemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Hypoglycemia - Pipeline by Biodel Inc., H2 2016
  • Hypoglycemia - Pipeline by Eiger BioPharmaceuticals, Inc., H2 2016
  • Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2016
  • Hypoglycemia - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Hypoglycemia - Pipeline by Novartis AG, H2 2016
  • Hypoglycemia - Pipeline by Sanofi, H2 2016
  • Hypoglycemia - Pipeline by SkyePharma Plc, H2 2016
  • Hypoglycemia - Pipeline by Therakind Limited, H2 2016
  • Hypoglycemia - Pipeline by USV Limited, H2 2016
  • Hypoglycemia - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016
  • Hypoglycemia - Pipeline by XOMA Corporation, H2 2016
  • Hypoglycemia - Pipeline by Zealand Pharma A/S, H2 2016
  • Hypoglycemia - Pipeline by Zosano Pharma Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Hypoglycemia - Dormant Projects, H2 2016
  • Hypoglycemia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Hypoglycemia, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top